Companies Engaged in Hepatitis B Vaccine & Therapeutics R&D

You can track the stock prices of publicly traded companies engaged in hepatitis B vaccine and therapeutics research and development with our new and unique "stock ticker." Please note that all prices shown may be delayed up to half an hour.

 

HBRI - Hepatitis B Research Index   $539.90   -2.815%  ▼
ALT - Altimmune, Inc.   $10.18   -6.820%  ▼
ARWR - Arrowhead Pharmaceuticals, Inc.   $31.90   -5.230%  ▼
ABUS - Arbutus Biopharma Corporation   $2.85   2.330%  ▲
ASMB - Assembly Biosciences, Inc.   $22.33   -0.290%  ▼
DRNA - Dicerna Pharmaceuticals, Inc.   $20.00   -8.170%  ▼
DVAX - Dynavax Technologies Corporation   $13.04   -0.530%  ▼
ENTA - Enanta Pharmaceuticals, Inc.   $46.31   0.520%  ▲
HEPA - Hepion Pharmaceuticals, Inc.   $0.46   3.430%  ▲
NTLA - Intellia Therapeutics, Inc.   $50.71   -4.190%  ▼
SBPH - Spring Bank Pharmaceuticals, Inc.   $1.46   -7.010%  ▼
VIR - Vir Biotechnology, Inc.   $27.53   0.660%  ▲
BBI - Brickell Biotech, Inc.   $0.91   -1.220%  ▼

Publicly Traded Companies

Listed below are the publicly traded companies we are tracking. If you have another to suggest, please email edward.tate@bblumberg.org.

ABUS - Arbutus Biopharma Corporation

ALT - Altimmune Inc.

ARWR - Arrowhead Pharmaceuticals Inc.

ASMB - Assembly Biosciences Inc.

BBI - Brickell Biotech Inc.

DRNA - Dicerna Pharmaceuticals Inc.

DVAX - Dynavax Technologies Corp.

ENTA - Enata Pharmaceuticals Inc.

HBRI - Hepatitis B Research Index
(market value-weighted representation of public companies listed)

HEPA - Hepion Pharmaceuticals Inc.

NTLA - Intellia Therapeutics Inc.

SBPH - Spring Bank Pharmaceuticals Inc.

VICL - Brickell Biotechnologies

VIRB - Vir Biotechnology Inc.

 

Note: Past performance is not indicative of future results. Neither the Pennsylvania Biotechnology Center, Hepatitis B Foundation nor the Baruch S. Blumberg Institute guarantees any specific outcome or profit. Stock or Index prices listed may fluctuate in price or value. You must make an independent decision regarding investments or strategies mentioned on this website. Individuals should consider whether it is suitable for their own particular circumstances and strongly consider seeking advice from your own financial or investment adviser.